Harrow, Inc. reported its financial results for the first quarter ended March 31, 2025, with total revenues reaching $47.8 million. This represents a 38% increase compared to the $34.6 million reported in the prior-year's first quarter. The company also reported record-high cash flow from operations of $19.7 million for the quarter.
Despite the strong revenue growth, Harrow reported a GAAP net loss of $(17.8) million for the first quarter. Adjusted for amortization costs, the loss was 38 cents per share. VEVYE revenues were a bright spot, rising 35% quarter-over-quarter to $21.5 million from $16.0 million in Q4 2024.
Mark L. Baum, CEO, reaffirmed the company's 2025 directional revenue guidance of 'over $280 million,' expecting revenues to accelerate quarter-over-quarter. He highlighted VEVYE's potential to become Harrow's largest revenue-generating product this year, with its Access for All program driving significant increases in new prescriptions and prescribers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.